Shohei Koide

Company: nyu langone health

Job title: Co-Founder of Aethon Bio & Professor, Grossman School of Medicine

Seminars:

Creating & Targeting Cancer-Specific Neoantigens with Covalent Inhibitors to Combine IO with Traditional Inhibition Approaches 11:15 am

Showcasing how covalent drugs such as KRAS(G12C) inhibitors can be designed to create cancer-specific neoantigens that can be targeted Displaying how antibodies that selectively recognize drug-peptide conjugates presented by multiple MHC types can be engineered to increase immune involvement Understanding how KRAS(G12C) drug resistant cancer cells can be selectively killed with bispecific T-cell engager antibodies…Read more

day: Day Two Track A AM